ライフサイエンスコーパス: corneal perforation

1 e scored on a scale of 0 (normal eye) to +4 (corneal perforation).

2 g Th2 response development are resistant (no corneal perforation).

3 s a vision-threatening complication, such as corneal perforation.

4 therapeutic keratoplasty, predominantly for corneal perforation.

5 Surgical alternative for the closure of corneal perforation.

6 .48%) for corneal melting, and 1 (0.83%) for corneal perforation.

7 scar size, time to re-epithelialization, and corneal perforation.

8 with uncontrolled fungal growth resulting in corneal perforation.

9 nterior chamber, and eventually resulting in corneal perforation.

10 tion of both NKT/NK cells results in earlier corneal perforation.

11 ficantly decreased vision and are at risk of corneal perforation.

12 ve with bandage contact lens application for corneal perforation.

13 tive surgical alternative for the closure of corneal perforations.

14 new surgical alternative for the closure of corneal perforations.

15 followed by previous surgery (30/49 [61%]), corneal perforation (17/49 [35%]), dry eye (15/49 [31%])

16 Of the 48 eyes, 21 had corneal perforation, 21 had severe corneal melting, and

17 of vision included corneal scarring (94.0%), corneal perforation (4.8%), and secondary glaucoma (1.2%

18 mography in the assessment of the healing of corneal perforation after surgical treatment by amniotic

19 mice, leading to a significant reduction in corneal perforation and improved disease outcome.

20 onjunctival flap surgery allowed us to avoid corneal perforation and penetrating keratoplasty (PK) a

21 IFN-gamma before infecting B6 mice prevented corneal perforation and was associated with a lower dela

22 val analysis was used to analyze the risk of corneal perforation and/or need for TPK.

23 .28 times the odds of the patient developing corneal perforation and/or needing TPK (95% CI, 1.18-4.4

24 ior one-third had a 71.4% risk of developing corneal perforation and/or needing TPK.

25 dentify those at highest risk for developing corneal perforation and/or needing TPK.

26 stics that predict a high risk of developing corneal perforation and/or the need to undergo therapeut

27 es included 3-month infiltrate or scar size; corneal perforation and/or therapeutic penetrating kerat

28 ity at 3 months; secondary outcomes included corneal perforation and/or therapeutic penetrating kerat

29 atients with fungal keratitis, patients with corneal perforation, and patients with infectious kerati

30 cuity (BSCVA), 3-month infiltrate/scar size, corneal perforation, and re-epithelialization rates stra

31 ration of disease, PUK activity, presence of corneal perforation, and treatments.

32 eek and 3-month visual acuity and scar size, corneal perforation, and/or the need for therapeutic pen

33 nation using confocal microscopy confirmed a corneal perforation at the left eye and revealed corneal

34 We excluded cases with preexisting corneal perforations before surgery.

35 ion, and 2 eyes of 2 patients presented with corneal perforation, both requiring a penetrating kerato

36 f resistant mice with TIMP-1 pAb resulted in corneal perforation by 5 to 7 days after infection (PI).

37 and all cases showed complete healing of the corneal perforation by AS-OCT within the 4-week follow-u

38 with epithelial ingrowth was as follows: (1) corneal perforation by hairs of the oak processionary mo

39 decreased corneal opacity and resistance to corneal perforation compared with PBS controls.

40 both at 3 weeks, 3 months, and 6 months; and corneal perforation (CP), the rate of therapeutic penetr

41 BL transplantation complicated by posterior corneal perforation demonstrated a corneal hydrops, evid

42 no hairs could be found histologically; (2) corneal perforation during laser-assisted blepharoplasty

43 +) T cells produce IFN-gamma contributing to corneal perforation in C57BL/6 (B6) mice after Pseudomon

44 valence rate of PED, corneal ulceration, and corneal perforation in chronic oGVHD to be 8.1%, 6.2%, a

45 s associated with genetic susceptibility and corneal perforation in inbred B6 mice.

46 ction with Pseudomonas aeruginosa results in corneal perforation in susceptible C57BL/6 (B6) mice, bu

47 de I prevents Pseudomonas aeruginosa-induced corneal perforation in susceptible C57BL/6 mice.

48 to worsened disease as evidenced by earlier corneal perforation in the susceptible mouse strain.

49 e patients in the control group demonstrated corneal perforation; infection recurred in 1 of them.

50 after HSCT included cataract, corneal ulcer, corneal perforation, lacrimal obstruction, herpetic kera

51 Severe ocular side effects, including corneal perforation, may be associated with the use of t

52 corneal patch keratoplasty for treatment of corneal perforation, melting and descemetocele.

53 eal ectasia (n = 15), failed graft (n = 15), corneal perforation (n = 11), and corneal scar following

54 In 1 case, corneal perforation occurred during the insertion of the

55 tment of corneal thinning was necessary, but corneal perforation occurred in two cases despite intens

56 ion, and treatment failure as progression to corneal perforation or keratoplasty.

57 rol group, whereas there was no incidence of corneal perforation or recurrence of the infection in th

58 The primary outcome of the trial was rate of corneal perforation or the need for therapeutic penetrat

59 primary outcome of the trial was the rate of corneal perforation or the need for therapeutic penetrat

60 Overall, no difference in the rate of corneal perforation or the need for TPK was determined f

61 e of this secondary analysis was the rate of corneal perforation or the need to undergo TPK.

62 13 eyes of 13 patients with small corneal perforation or thinning were included in the stu

63 ease criteria) and safety (ocular infection, corneal perforation, or graft detachment).

64 fined as final visual acuity (VA) </= 20/80, corneal perforation, or need for keratoplasty.

65 was defined as final visual acuity </=20/80, corneal perforation, or the need for keratoplasty.

66 s a case in which sudden axial proptosis and corneal perforation revealed underlying GPA.

67 of mice were susceptible to infection, with corneal perforation seen at 5 to 7 days after infection.

68 an essential tool to confirm healing of the corneal perforation surgically treated by amniotic membr

69 Pseudomonas aeruginosa stromal keratitis and corneal perforation (susceptibility) is a CD4(+) T cell-

70 exhibited a less severe disease response (no corneal perforation) than wild-type B6 mice and had a si

71 and then the E-PRP clot was placed over the corneal perforation, underneath the fibrin membrane.

72 During follow-up, the rate of corneal perforation was 0.009/EY.

73 Corneal perforation was more common in cases (52.17% [12

74 the disease response of both strains, where corneal perforation was prevented in B6 mice, and BALB/c

75 In all cases the corneal perforation was sealed.

76 Patients with perforation/impending corneal perforation were excluded from the study.

77 however, significant differences leading to corneal perforation were seen in BALB/c mice that includ

78 FGF, and HGF after disease onset, prevented corneal perforation when compared with controls.

79 TEM revealed full thickness corneal perforation with an epithelial plug extending to

80 njunctival congestion, chemosis, and a small corneal perforation with iris prolapse and a flat anteri